Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma
Open Access
- 18 December 2015
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 5 (2), 192-199
- https://doi.org/10.1002/cam4.577
Abstract
To describe the clinical characteristics, treatment patterns and outcomes in advanced small cell bladder cancer (aSCBC) patients and compare to those with urothelial carcinoma (UC). Individuals in the National Cancer Data Base with a diagnosis of either nodal (TxN+M0) or distant metastatic (TxNxM1) disease were identified from 1998 to 2010. We assessed the relationships between stage, treatment modalities and survival in the aSCBC cohort and compared these to UC patients. In the 960 patient aSCBC cohort (62% M1), 50% received palliative therapy alone, 68% in M1 versus 21% in M0 groups (P < 0.0001). Single modality local therapy (15%) and surgical (21%) or radiation-based (14%) multimodal therapy (MMT) were used in the other 50%. Cystectomy-based MMT was utilized in 45% of N+M0 versus 6.4% of NxM1 patients (P < 0.0001). Median overall survival (OS) for aSCBC patients was 8.6 months; 13.0 months in N+M0 versus 5.3 months in NxM1 patients (P < 0.0001). Survival was similar between TxN1M0 and TxN2-3M0 patients (14.8 months vs. 12.1 months, P = 0.15). Urothelial carcinoma patients (n = 27,796, 45% M1) lived longer compared to aSCBC patients in the N+M0 group (17.3 months vs. 13.0 months, P = 0.0007). There were not clinically significant differences in OS between UC and aSCBC patients in the M1 group. Advanced SCBC is a rare disease with a poor survival and palliative therapy is common, especially in M1 patients. In comparison to UC, the outcomes for aSCBC patients are worse in those with lymph node only involvement but similar in those with distant disease.Keywords
Funding Information
- National Cancer Institute (P30CA006927)
This publication has 33 references indexed in Scilit:
- Local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladderInternational Journal of Urology, 2012
- A Surveillance, Epidemiology, and End Results analysis of small cell carcinoma of the bladderCancer, 2011
- Outcome of recurrent and metastatic small cell carcinoma of the bladderBMC Urology, 2009
- Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial CancerJournal of Clinical Oncology, 2009
- Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer CenterBJU International, 2006
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Small cell carcinoma of the urinary bladderCancer, 2005
- The National Cancer Data Base: A clinical surveillance and quality improvement toolJournal of Surgical Oncology, 2003
- Small Cell Carcinoma of the Urinary Bladder Treated with Chemotherapy and Radiotherapy: Results in Five CasesEuropean Urology, 1999